Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Ischemic Heart Disease (IHD)Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Ischemic Heart Disease (IHD)Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Anti-dyslipidemic Drugs
      • 1.3.3 Calcium Channel Blockers
      • 1.3.4 Beta-blockers
      • 1.3.5 ACE Inhibitors
      • 1.3.6 ARBs
      • 1.3.7 Vasodilators
      • 1.3.8 Antithrombotic Agents
    • 1.4 Market Segment by Application
      • 1.4.1 Global Ischemic Heart Disease (IHD)Drugs Market Share by Application (2019-2025)
      • 1.4.2 Stable Angina
      • 1.4.3 Unstable Angina
      • 1.4.4 Prinzmetal's Angina
      • 1.4.5 STEMI
      • 1.4.6 NSTEMI
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Ischemic Heart Disease (IHD)Drugs Market Size
      • 2.1.1 Global Ischemic Heart Disease (IHD)Drugs Revenue 2014-2025
      • 2.1.2 Global Ischemic Heart Disease (IHD)Drugs Sales 2014-2025
    • 2.2 Ischemic Heart Disease (IHD)Drugs Growth Rate by Regions
      • 2.2.1 Global Ischemic Heart Disease (IHD)Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Ischemic Heart Disease (IHD)Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Ischemic Heart Disease (IHD)Drugs Sales by Manufacturers
      • 3.1.1 Ischemic Heart Disease (IHD)Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Ischemic Heart Disease (IHD)Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Ischemic Heart Disease (IHD)Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Ischemic Heart Disease (IHD)Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Ischemic Heart Disease (IHD)Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Ischemic Heart Disease (IHD)Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Ischemic Heart Disease (IHD)Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Ischemic Heart Disease (IHD)Drugs Market
    • 3.6 Key Manufacturers Ischemic Heart Disease (IHD)Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Anti-dyslipidemic Drugs Sales and Revenue (2014-2019)
      • 4.1.2 Calcium Channel Blockers Sales and Revenue (2014-2019)
      • 4.1.3 Beta-blockers Sales and Revenue (2014-2019)
      • 4.1.4 ACE Inhibitors Sales and Revenue (2014-2019)
      • 4.1.5 ARBs Sales and Revenue (2014-2019)
      • 4.1.6 Vasodilators Sales and Revenue (2014-2019)
      • 4.1.7 Antithrombotic Agents Sales and Revenue (2014-2019)
    • 4.2 Global Ischemic Heart Disease (IHD)Drugs Sales Market Share by Type
    • 4.3 Global Ischemic Heart Disease (IHD)Drugs Revenue Market Share by Type
    • 4.4 Ischemic Heart Disease (IHD)Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Ischemic Heart Disease (IHD)Drugs Sales by Application

    6 United States

    • 6.1 United States Ischemic Heart Disease (IHD)Drugs Breakdown Data by Company
    • 6.2 United States Ischemic Heart Disease (IHD)Drugs Breakdown Data by Type
    • 6.3 United States Ischemic Heart Disease (IHD)Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Ischemic Heart Disease (IHD)Drugs Breakdown Data by Company
    • 7.2 European Union Ischemic Heart Disease (IHD)Drugs Breakdown Data by Type
    • 7.3 European Union Ischemic Heart Disease (IHD)Drugs Breakdown Data by Application

    8 China

    • 8.1 China Ischemic Heart Disease (IHD)Drugs Breakdown Data by Company
    • 8.2 China Ischemic Heart Disease (IHD)Drugs Breakdown Data by Type
    • 8.3 China Ischemic Heart Disease (IHD)Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Ischemic Heart Disease (IHD)Drugs Breakdown Data by Company
    • 9.2 Rest of World Ischemic Heart Disease (IHD)Drugs Breakdown Data by Type
    • 9.3 Rest of World Ischemic Heart Disease (IHD)Drugs Breakdown Data by Application
    • 9.4 Rest of World Ischemic Heart Disease (IHD)Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Ischemic Heart Disease (IHD)Drugs Sales by Countries
      • 9.4.2 Rest of World Ischemic Heart Disease (IHD)Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 AstraZeneca
      • 10.1.1 AstraZeneca Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Ischemic Heart Disease (IHD)Drugs
      • 10.1.4 Ischemic Heart Disease (IHD)Drugs Product Introduction
      • 10.1.5 AstraZeneca Recent Development
    • 10.2 Bayer
      • 10.2.1 Bayer Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Ischemic Heart Disease (IHD)Drugs
      • 10.2.4 Ischemic Heart Disease (IHD)Drugs Product Introduction
      • 10.2.5 Bayer Recent Development
    • 10.3 Eli Lilly
      • 10.3.1 Eli Lilly Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Ischemic Heart Disease (IHD)Drugs
      • 10.3.4 Ischemic Heart Disease (IHD)Drugs Product Introduction
      • 10.3.5 Eli Lilly Recent Development
    • 10.4 Novartis
      • 10.4.1 Novartis Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Ischemic Heart Disease (IHD)Drugs
      • 10.4.4 Ischemic Heart Disease (IHD)Drugs Product Introduction
      • 10.4.5 Novartis Recent Development
    • 10.5 Pfizer
      • 10.5.1 Pfizer Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Ischemic Heart Disease (IHD)Drugs
      • 10.5.4 Ischemic Heart Disease (IHD)Drugs Product Introduction
      • 10.5.5 Pfizer Recent Development
    • 10.6 Sanofi
      • 10.6.1 Sanofi Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Ischemic Heart Disease (IHD)Drugs
      • 10.6.4 Ischemic Heart Disease (IHD)Drugs Product Introduction
      • 10.6.5 Sanofi Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Ischemic Heart Disease (IHD)Drugs Sales Channels
      • 11.2.2 Ischemic Heart Disease (IHD)Drugs Distributors
    • 11.3 Ischemic Heart Disease (IHD)Drugs Customers

    12 Market Forecast

    • 12.1 Global Ischemic Heart Disease (IHD)Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Ischemic Heart Disease (IHD)Drugs Sales Forecast by Type
    • 12.3 Global Ischemic Heart Disease (IHD)Drugs Sales Forecast by Application
    • 12.4 Ischemic Heart Disease (IHD)Drugs Forecast by Regions
      • 12.4.1 Global Ischemic Heart Disease (IHD)Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Ischemic Heart Disease (IHD)Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Ischemic heart disease (IHD), refers to a group of diseases which includes stable angina, unstable angina, myocardial infarction, and sudden cardiac death. It is within the group of cardiovascular diseases of which it is the most common type. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.
      Ways to reduce CAD risk include eating a healthy diet, regularly exercising, maintaining a healthy weight, and not smoking. Medications for diabetes, high cholesterol, or high blood pressure are sometimes used. Additional medications such as antiplatelets, beta blockers, or nitroglycerin may be recommended.
      In 2019, the market size of Ischemic Heart Disease (IHD)Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Ischemic Heart Disease (IHD)Drugs.

      This report studies the global market size of Ischemic Heart Disease (IHD)Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Ischemic Heart Disease (IHD)Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      AstraZeneca
      Bayer
      Eli Lilly
      Novartis
      Pfizer
      Sanofi
      ...

      Market Segment by Product Type
      Anti-dyslipidemic Drugs
      Calcium Channel Blockers
      Beta-blockers
      ACE Inhibitors
      ARBs
      Vasodilators
      Antithrombotic Agents

      Market Segment by Application
      Stable Angina
      Unstable Angina
      Prinzmetal's Angina
      STEMI
      NSTEMI

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Ischemic Heart Disease (IHD)Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Ischemic Heart Disease (IHD)Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Ischemic Heart Disease (IHD)Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now